FDA Okays Treatment-Resistant Depression Indication for Combo Pill
2009-04-01
A new indication for treatment-resistant depression in adults has been added to the olanzapine/fluoxetine combination pill (Symbyax), the drugmaker Eli Lilly announced.
The combination drug was the first approved by the FDA for bipolar disorder in 2003, and is now the first okayed for treatment-resistant depression.